

[Clinical pathology selected abstracts](#)

written by CAP TODAY

March 17, 2024

March 2024—Despite research into colorectal cancer screening and clinical experience, screening uptake remains low. Colorectal cancer (CRC) screening involves noninvasive tests, such as a fecal immunochemical test (FIT) and stool-based DNA tests, as well as invasive tests, such as colonoscopy. The latter has the best performance characteristics for early cancer and adenoma detection. The average adherence to CRC screening is 60.6 percent for U.S. patients aged 50 to 75 years, which is well below the 80 percent goal for adherence set by the National Colorectal Cancer Roundtable and American Cancer Society. Offering stool-based tests to patients who refuse colonoscopy results in only a modest increase in adherence, to 67 percent.



©2026 CAP TODAY, all rights reserved.

[Anatomic pathology selected abstracts](#)

written by CAP TODAY

March 17, 2024

March 2024—Lung transplantation is the definitive therapy for end-stage pulmonary sarcoidosis. While several case reports have described recurrent sarcoidosis in allografts, the incidence and clinicopathologic characteristics remain unclear. The authors conducted a study in which they characterized the clinical and histopathologic features of recurrent sarcoidosis diagnosed in post-transplant lung surveillance transbronchial biopsies (TBBx). They identified 35 patients who underwent lung transplant for pulmonary sarcoidosis during the study period. Eighteen (51 percent) of the patients experienced recurrent sarcoidosis post-transplant—seven females and 11 males (mean age at recurrence, 51.6 years).



©2026 CAP TODAY, all rights reserved.

[Molecular pathology selected abstracts](#)

written by CAP TODAY
March 17, 2024

March 2024—Human epidermal growth factor receptor 2 is a critical biomarker in breast cancer, gastrointestinal malignancies, and other cancers. HER2 protein expression can be evaluated using IHC, and the DNA copy number of its encoding gene, *ERBB2*, can be evaluated using FISH. In most clinical settings, IHC evaluation is categorized as positive (3+), equivocal (2+), or negative (0 to 1+), with equivocal cases being reflexed to FISH. Patients with HER2-positive tumors, defined as either 3+ or 2+/FISH positive, have been eligible to receive HER2-targeted therapy for many years. More recently, the FDA approved the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) to treat patients with HER2-low breast cancer, defined as tumors with IHC 1+ or 2+/FISH negative. This promising treatment has allowed many more patients to receive molecular-targeted therapy.



©2026 CAP TODAY, all rights reserved.

[Q&A column](#)

written by CAP TODAY
March 17, 2024

March 2024

Q. Is it a requirement that routine bacteriology cultures (for example, urine, sputum) be plated in a biological safety cabinet in your typical hospital biosafety level 2 laboratory? Is it safe to read these cultures on an open bench? [Read answer.](#)

Q. What source should a laboratory use for reference intervals for analytes? [Read answer.](#)



Newsbytes

written by CAP TODAY
March 17, 2024

March 2024—While Dr. Seuss’ assertion that “the more that you read, the more things you will know” is generally accurate, it doesn’t address the fact that how information is presented affects comprehension, a truism that is not lost on Edward Klatt, MD, who knows whereof he speaks when it comes to sharing information on patient portals.



©2026 CAP TODAY, all rights reserved.

Put It on the Board

written by CAP TODAY
March 17, 2024

March 2024—The Food and Drug Administration approved in December the AvertD test, which assesses whether an individual may have an elevated risk of developing opioid use disorder. Its intended use is to inform the decision-making of patients and physicians about the use of oral opioids for acute pain relief.



©2026 CAP TODAY, all rights reserved.

Roche debuts Navify solutions at HIMSS24

written by CAP TODAY
March 17, 2024

March 15, 2024—Roche debuted its Navify Analytics for POC and Navify Monitoring solutions at the Healthcare Information and Management Systems Society global health conference in Orlando, March 11-15.



©2026 CAP TODAY, all rights reserved.

Sekisui gets EUA for Osom flu, SARS-CoV-2 test

written by CAP TODAY
March 17, 2024

March 13, 2024—Sekisui Diagnostics received EUA clearance for its Osom Flu SARS-CoV-2 Combo test for use in professional and home testing settings.



©2026 CAP TODAY, all rights reserved.

New ASCCP guidelines now include dual-stain

[triage testing](#)

written by CAP TODAY
March 17, 2024

March 12, 2024—[Roche Diagnostics](#) announced the release of new guidelines from the American Society for Colposcopy and Cervical Pathology and other members of the Enduring Consensus Cervical Cancer Screening and Management Guidelines committee that now recognize dual-stain biomarkers as an important technology in helping clinicians triage patients to determine if their human papillomavirus infection is transforming into cervical precancer.



©2026 CAP TODAY, all rights reserved.

[BD Biosciences releases RealBlue reagents](#)

written by CAP TODAY
March 17, 2024

March 2024—BD Biosciences has released its BD Horizon RealBlue 744 and 705 laser-specific reagents, designed to reduce spillover and well suited for low- to medium-expression surface and intracellular markers. RB 744 can be used on five-laser BD FacSymphony analyzers and spectral flow cytometers. RealBlue 705 is an alternative to BD PerCP-Cy5.5 and BD Brilliant Blue 700 reagents and is compatible with conventional and spectral flow cytometry.



©2026 CAP TODAY, all rights reserved.